AstraZeneca to discover and develop novel therapies targeting RNA-modifying proteins in oncology collaboration with Accent Therapeutics
AstraZeneca will collaborate with Accent Therapeutics to discover, develop and commercialise transformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer. This collaboration focuses on targeting RMPs, proteins that control many aspects of RNA biology and represents a new approach for addressing the process disruptions that can lead to cancer and can cause resistance to medicines. It combines AstraZeneca’s industry leading expertise bringing forward novel oncology medicines with Accent’s expertise as a leader in the biology, target identification and